| 产品描述: | IV-361 is an orally active and selective CDK7 inhibitor (Ki≤50 nM). IV-361 has anti-cancer activity (US20190256531A1)[1]. |
| 靶点: |
CDK7:≤50 nM (Ki);CDK2:≥1000 nM (Ki) |
| 体外研究: |
IV-361 (25 mg/kg/day; orally) exhibits 46% or more rate of suppression of tumor volume in female BALB nude mice with HCT-116[1]. |
| 体内研究: |
IV-361 has less inhibition on CDK2 (Ki≥1000 nM) or PLK1 (Ki≥5000 nM)[1]. IV-361 exhibits excellent IL-2 and IL-17 production inhibitory activity (all IC50≤100 nM) in periphery blood mononuclear cell (PBMC)[1]. IV-361 exhibits excellent HCT-116 cell growth inhibitory activity (GI50≤100 nM)[1]. |
| 参考文献: |
1. Noriaki Iwase, et al. Substituted dihydropyrrolopyrazole derivative. US20190256531A1. |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.185 ml |
10.926 ml |
21.852 ml |
| 5 mM |
0.437 ml |
2.185 ml |
4.37 ml |
| 10 mM |
0.219 ml |
1.093 ml |
2.185 ml |
| 50 mM |
0.044 ml |
0.219 ml |
0.437 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |